In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 221 to 230 of 404

TitleTypeExpected publication date
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221Technology appraisal guidance
Nemolizumab for treating prurigo nodularis [ID6451]Technology appraisal guidance
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Technology appraisal guidanceTBC
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Technology appraisal guidance
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]Technology appraisal guidanceTBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]Technology appraisal guidanceTBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All